PANTHERx® Rare Becomes Chiesi's Exclusive Partner for MYCAPSSA® Distribution PANTHERx® Rare has been appointed by Chiesi as the exclusive specialty pharmacy for MYCAPSSA®, enhancing access for acromegaly patients.

PANTHERx® Rare Becomes Chiesi's Exclusive Partner for MYCAPSSA® Distribution #United_States #Pittsburgh #PANTHERx_Rare #Chiesi_Group #MYCAPSSA

Elgan Pharma and Chiesi Group Start Pivotal Phase 3 Study for Preterm Infants Elgan Pharma and Chiesi Group jointly announced the initiation of a Phase 3 clinical study, ELGN-2112, targeting intestinal malabsorption in preterm infants. Aimed at improving their health outcomes, this study seeks to redefine treatments.

Elgan Pharma and Chiesi Group Start Pivotal Phase 3 Study for Preterm Infants #Israel #Nazareth #Chiesi_Group #ELGN-2112 #Elgan_Pharma

Chiesi Global Rare Diseases to Showcase Groundbreaking Research at WORLDSymposium 2025 Chiesi Global Rare Diseases will present 11 important abstracts at the upcoming 21st Annual WORLDSymposium, focusing on Fabry disease and alpha-mannosidosis.

Chiesi Global Rare Diseases to Showcase Groundbreaking Research at WORLDSymposium 2025 #Italy #Rare_Diseases #Parma #Chiesi_Group #WORLDSymposium